These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24060523)

  • 1. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
    Masaki M; Mano T; Eguchi A; Fujiwara S; Sugahara M; Hirotani S; Tsujino T; Komamura K; Koshiba M; Masuyama T
    Heart Vessels; 2016 Nov; 31(11):1826-1833. PubMed ID: 26825736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
    Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM; Germino FW; Smith D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
    Mori M; Takahashi S
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
    [No Abstract]   [Full Text] [Related]  

  • 11. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
    Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
    Taniguchi I; Kawai M; Date T; Yoshida S; Seki S; Taniguchi M; Shimizu M; Mochizuki S
    Circ J; 2006 Aug; 70(8):995-1000. PubMed ID: 16864931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
    Matsui K; Kim-Mitsuyama S; Ogawa H; Jinnouchi T; Jinnouchi H; Arakawa K;
    Hypertens Res; 2014 Jun; 37(6):526-32. PubMed ID: 24599010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
    Yamabe H; Kaikita K; Matsumura T; Iwasa A; Koyama J; Uemura T; Morikami Y; Tsunoda R; Morihisa K; Fujimoto K; Kajiwara I; Matsui K; Tsujita K; Ogawa H
    J Cardiol; 2018 Feb; 71(2):129-134. PubMed ID: 28886992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
    Gartenmann AC; Fossali E; von Vigier RO; Simonetti GD; Schmidtko J; Edefonti A; Bianchetti MG
    Kidney Int; 2003 Oct; 64(4):1450-4. PubMed ID: 12969165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
    Yoshida C; Goda A; Naito Y; Nakaboh A; Matsumoto M; Otsuka M; Ohyanagi M; Hirotani S; Lee-Kawabata M; Tsujino T; Masuyama T
    J Hypertens; 2011 Feb; 29(2):357-63. PubMed ID: 21052021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.